With membership, Tongji University to get exclusive access to MilliporeSigma’s genome-editing technology, comprehensive technical support University joins a network of 70 CRISPR core labs around the world MilliporeSigma, a leading science and technology company and leader in genome editing, today announced a new CRISPR core partnership with Tongji University in Shanghai. Tongji University is the... Read more
https://www.biomax.com/lib/press-releases/201806_NeuroXM.pdf Read more
June 14, 2018 Singapore, 30th day of May 2018: Shimadzu (Asia Pacific) Pte Ltd, the longest-serving global leader in providing analytical solutions, scientific equipment, testing machines, balances and medical equipment, has signed a three-year Memorandum of Understanding (MoU) with Singapore Polytechnic’s (SP) School of Chemical and Life Sciences (CLS), to create a SMART (Scalable Manageable Automated... Read more
Basel, 13 June 2018 FDA approves Roche’s Avastin (bevacizumab) plus chemotherapy as a treatment for women with advanced ovarian cancer following initial surgery Avastin is now approved for ten distinct uses across six different types of cancer in the United States Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the US Food and Drug... Read more
Basel, 13 June 2018 FDA approves Roche’s Avastin (bevacizumab) plus chemotherapy as a treatment for women with advanced ovarian cancer following initial surgery Avastin is now approved for ten distinct uses across six different types of cancer in the United States Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the US Food and Drug... Read more
Agilent Companion Diagnostic Gains Expanded FDA Approval in Cervical Cancer PD-L1 IHC 22C3 pharmDx can now be used as an aid to identify cervical cancer patients for treatment with KEYTRUDA® (pembrolizumab) SANTA CLARA, Calif., June 12, 2018 Agilent Technologies Inc. (NYSE: A) today announced that the U.S. Food and Drug Administration (FDA) has approved its... Read more
FRANKFURT, Germany, June 11, 2018 /PRNewswire/ — At ACHEMA 2018, Bruker today announces the launch of the new S6 JAGUAR™, an exceptionally powerful and versatile benchtop Wavelength Dispersive X-Ray Fluorescence (WDXRF) spectrometer. The S6 JAGUAR extends Bruker’s range of XRF instruments by closing the gap between floor standing WDXRF and benchtop EDXRF instruments. It combines excellent... Read more
Basel, 11 June 2018 Roche announces FDA approval for Venclexta plus Rituxan for people with previously treated chronic lymphocytic leukaemia Approval based on phase III MURANO study showing Venclexta plus Rituxan reduced risk of disease progression or death by 81% compared to bendamustine plus Rituxan Roche (SIX: RO, ROG; OTCQX: RHHBY), announced today that the... Read more
Basel, 11 June 2018 Roche announces FDA approval for Venclexta plus Rituxan for people with previously treated chronic lymphocytic leukaemia Approval based on phase III MURANO study showing Venclexta plus Rituxan reduced risk of disease progression or death by 81% compared to bendamustine plus Rituxan Roche (SIX: RO, ROG; OTCQX: RHHBY), announced today that the... Read more
Basel, 05 June 2018 FDA grants Priority Review to Roche’s Hemlibra for people with haemophilia A without factor VIII inhibitors Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the US Food and Drug Administration (FDA) has accepted the company’s supplemental Biologics License Application (sBLA) and granted Priority Review for Hemlibra® (emicizumab-kxwh) for adults and... Read more